Study information
This is a Non-interventional treatment Registry of HAE patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest). The objectives are to observe adverse events, including lack of efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest in patients diagnosed with HAE.
Partnership
SOBI
Web: www.sobi.com
Email:
Pharming Technologies B.V
Web: www.pharming.com
Email: